Our Leadership

Amy Jackson is Head of Government Affairs and Policy for Pharmaceuticals, Asia Pacific; and is a member of the Janssen Asia Pacific Leadership Team. Amy joined Janssen in October 2021 and is responsible for fostering collaborations between the Market Access, Government and Policy functions across the region; and proactively shaping the access policy environment, whilst establishing key relationships with influencers and decision makers.

Originally from the United States, Amy maintains a deep understanding of Asia Pacific markets, having served as President of the American Chamber of Commerce in Korea (AMCHAM Korea) for six years, prior to her role as the Japan Representative for the Pharmaceutical Research and Manufacturers of America (PhRMA) association. Prior to these roles, Amy worked at the Office of the U.S. Trade Representative (USTR) serving as a U.S. trade negotiator with Japan and Korea.

Amy holds a master’s degree in International Relations from Johns Hopkins University and a bachelor’s degree in Government from Pomona College; she also currently serves as a Vice President of the American Chamber of Commerce in Japan (ACCJ) and as a member of the Maureen and Mike Mansfield Foundation Board of Directors.

Urs is a strategic thinker and collaborative leader with a focus on building high performing teams and a passion for innovation. He has more than 15 years of industry experience across sales, marketing and business unit leadership roles that span multiple therapeutic areas and geographies; and a consistent track record of commercial success. Prior to his current role, Urs was Managing Director of the Switzerland business.

Urs has shown a commitment to shaping the external environment through long-term partnerships with stakeholders. He is passionate about fostering an inclusive work culture and served as Executive sponsor for the Alliance for Diverse Abilities (ADA) Employee Resource Group.

Urs graduated in 2006 with a Master of Business Administration and Communication Sciences from the University of Zurich, Switzerland. He further graduated at INSEAD, Fontainebleau, France in General Management.

Carmen is a highly regarded strategic HR Leader with a proven track record in delivering innovative, people-focused strategies and solutions.

As Head of Human Resources for Pharmaceuticals at Janssen Asia Pacific, Carmen leads the regional strategic talent agenda and is responsible for enhancing the company’s organizational capabilities.

In her previous role as Head of HR for Janssen’s Asia Pacific Supply Chain, Carmen led various change initiatives including organization design, human capital planning, and employee well-being and resilience

She also delivered targeted strategies and programs to advance talent, grow diverse leadership and build new capabilities. This resulted in a stronger talent pipeline and a high performing, engaged workforce.

A passionate innovator, Carmen has also served as Head of HR for One J&J Southeast Asia, where she played a critical role in the design and implementation of the One J&J business model.

Carmen joined J&J in 2012 as Talent Director for Janssen Asia Pacific. She holds a Bachelor of Business in Human Resources Management from Nanyang Technological University in Singapore.

Lee Yee Khun (Yeek) is Vice President, Janssen Supply Chain Asia Pacific. Yeek is part of the Janssen Supply Chain and Janssen Asia Pacific Leadership Teams.

In this role, Yeek will lead the development and execution of an integrated Janssen Supply Chain Asia Pacific strategy and oversee all Supply Chain functions in the region, including Customer Management, Value Chain Management, and Manufacturing. Yeek will partner with the Commercial teams to ensure that our supply chain will continue to give robust support for rapid regional growth.

Most recently, Yeek is the E2E Supply Chain Leader for the APeJC (APAC excluding Japan and China) cluster which brings together highly diverse markets with multiple regulatory systems to support the growth in APAC. Yeek established the APeJC Supply Chain Leadership Team to enable single point of contact for each commercial market. This ensured clear accountability as Janssen supported the strong growth in the cluster. With a clear supply chain strategy and purpose, he has driven process standardization and efficiency to advance the digital agenda by delivering automated dashboard reporting and clear issues management protocols. Yeek is also the regional supply chain sponsor for the implementation of the IBP program deployment and supported the OMP rollout for the region.

Yeek joined Johnson & Johnson in 2020 from Mars Incorporated where he held multiple leadership positions within the supply chain function.

For the past 25 years, Chris has made a meaningful difference to the lives of patients by working collaboratively with a range of health and pharmaceutical stakeholders to establish access to and ensure the quality use of innovative medicines.

This passion continues today in his role as a member of the Pharmaceuticals Global Operating Committee and as Company Group Chairman for Janssen Asia Pacific, where he oversees pharmaceutical operations for Johnson & Johnson in the world’s most diverse and populous region.

Prior to leading Janssen in eight markets across Asia Pacific, Chris was President of Janssen Japan – the second largest market for Janssen globally – for five years. In this period, he improved the company’s market competitiveness, widened access to innovative medicines, and attracted and developed the strongest of talent.

Chris is a highly respected member of the pharmaceutical industry, having chaired PhRMA Japan and worked as a board member of EFPIA Japan, Medicines Australia and Medicines New Zealand to highlight the value of pharmaceutical innovation and advocate for medicines access.

Since joining Janssen Australia in 2005, Chris has worked across five countries in positions of increasing responsibility. He has previously led Janssen operations in Japan, Australia & New Zealand, Vietnam, and New Zealand. He also worked in the United States as Global Marketing Lead for the Janssen Psychiatry business unit.

Chris holds a Master of Business Administration and a Bachelor of Applied Science from the University of Technology, Sydney, Australia.

Chris is based in Singapore.

Cherry is an accomplished leader recognized for her strong business acumen, support for patient centric innovation and a passion for talent development.

As Area Managing Director for Janssen North Asia, Cherry Huang is responsible for delivering long-term sustainable growth for operations in Korea, Taiwan and Hong Kong.

Previously Vice President for Finance, Janssen Asia Pacific, Cherry was instrumental in setting business strategy and overseeing financial stewardship to drive accelerated growth across the region’s pharmaceuticals business.

Prior to this, Cherry was Senior Finance Director of Johnson & Johnson Southeast Asia, where she was instrumental in shaping the governance model of the new entity and identifying key growth drivers across SEA markets in partnership with commercial leaders.

Before taking on her role in Southeast Asia, Cherry was the Senior Finance Director of Xian Janssen. In this position, she played a key role in the improved performance of our China business, which recorded year-on-year growth under her financial leadership.

Cherry holds a Bachelor of Science degree in Finance from Shanghai Jiao Tong University and an MBA from the Booth School of Business, University of Chicago, and has held a number of roles in finance within J&J across Asia Pacific, Europe and North America.

George Power is Vice President Law for Janssen Asia Pacific, where he is responsible for the legal affairs of the Pharmaceuticals group in the region. George started his Johnson & Johnson career in 2010 as Senior Counsel for the Pharmaceuticals and Medical Devices businesses in Australia and New Zealand, serving on the leadership teams of those businesses.

Over the past decade at Johnson & Johnson, George has advised on a wide range of complex matters and has taken on roles of increasing responsibility, including the leadership and development of a cross-sector, cross-regional team and the provision of strategic counsel to the One Johnson & Johnson Southeast Asia leadership team, of which he was a member from shortly after its inception until 2020. Since 2018, George has also served as a member of the Johnson & Johnson Law Department Management Committee.

George has an outstanding record of providing strategic business counsel, as well as being a strong advocate of civil justice reform in Australia. Prior to joining Johnson & Johnson, George was Assistant General Counsel, EMEA and Asia Pacific for CooperVision.

George also practiced law in London at CMS Cameron McKenna and in Sydney at Mallesons Stephen Jaques. He received his law degree from the University of New England (New South Wales, Australia) and has qualified as a solicitor in Australia and England.

HyangWon (Harriet) Min is Vice President of Regulatory Affairs Asia Pacific. She is responsible for leading the regional regulatory affairs organization covering all therapeutic areas in the Asia Pacific region. She is also a member of the Global Regulatory Affairs Senior Leadership Team.

Harriet joined Janssen Korea in 2013 as Director of Regulatory Affairs and Business Quality, and she transitioned to the role of Senior Director, Regulatory & Medical Affairs for Janssen Korea in 2019. Under her leadership, the Medical Affairs, as well as the Regulatory Affairs and Commercial Quality teams, have been continuously recognized as high performing organizations using innovative approaches and strong cross-functional collaborations.

Prior to joining Janssen, Harriet gained extensive experience in the pharmaceutical and medical device industry, holding leadership roles in various functions including Regulatory Affairs, Pharmacovigilance, Market Access, and Quality Assurance. Prior to joining the pharmaceutical industry, Harriet served as a pharmacist for two years.

Harriet received her Bachelor of Science and Master of Science degrees in Pharmacy from Seoul National University, Seoul, South Korea.

Andrew leads the Pharmaceutical Communication and Public Affairs team (C&PA) across Asia Pacific to deliver powerful strategies that support patients, enhance access and accelerate the business.  The team is also charged with building and protecting the long-term reputation of Janssen with both internal and external stakeholders.

Most recently, Andrew served as the senior C&PA counsellor to the Johnson & Johnson Japan President’s Council, and Chair of the Japan Community Impact Organization.  In this role he was responsible for building, strengthening and shaping Johnson & Johnson’s reputation and communication efforts in Japan across the company’s entire MedTech, Consumer and Pharmaceuticals portfolio.

During his 14+ years at Johnson & Johnson, Andrew has worked in commercial, communications and government affairs functions. Before his time in Japan, he completed five years in the USA, initially in the global pharmaceuticals team where he directly supported the Worldwide Chairman, including staffing him as Chairman of PhRMA. He also held leadership roles for critical milestones such as the acquisition of Actelion (J&J’s largest ever acquisition), the development and launch of the business’ new global strategy and key reviews with the investment community. Subsequently he led communications teams in three of the company’s North American pharmaceutical business units. During this time, he developed a new approach to U.S. pharmaceutical TV advertising and helped pioneer new communications approaches for major issues.

Prior to his US assignment, Andrew led the transition and change management of the Janssen ANZ business to a more customer-focused model, creating and leading a team responsible for customer insights, customer experience design and multichannel marketing. He also founded the Janssen Health and Technology Challenge (HaTCH) which sought to inspire start-ups to solve healthcare challenges facing Australia.

Andrew holds Bachelor of Media and Bachelor of Laws degrees, Honours 1st Class, from Macquarie University; and graduated at the top of his MBA class from Macquarie Graduate School of Management.

Jenny is a results-oriented leader whose passion for nurturing high-performing teams has left an indelible mark on the markets and teams she has overseen throughout her career with Janssen.

As President of Xian Janssen, Jenny Zheng oversees operations in the People’s Republic of China. She is also a member of the Asia Pacific Leadership Team.

Since joining Xian Janssen as a marketing manager in 2002, Jenny has served in numerous leadership roles at regional and country levels, including Managing Director of Janssen Taiwan and, most recently, Area Managing Director of Janssen Korea, Taiwan and Hong Kong.

Under her leadership, Janssen Korea was one of the fastest growing multinational companies in 2019 and 2020. In Taiwan, Janssen improved its market ranking by two positions to become the sixth largest pharmaceutical company, and in Hong Kong, Janssen ranked as the fastest growing among the top 10 companies.

During this time, Jenny also served as Co-chair of the Pharmaceutical Committee, AmCham (The American Chamber of Commerce) Taipei, and was Board Director for the International Research-based Pharmaceutical Manufacturers Association (IRPMA) Taiwan, and Korean Research-based Pharmaceutical Industry Association.

Jenny is also a passionate volunteer in the local community. She was awarded the Volunteer Star as Enterprise Senior Leaders by the Beijing Civil Volunteer Service Center in 2015.

Jenny holds an Engineering degree from Shanghai JiaoTong University, and an MBA with Honors from the Booth School of Business, University of Chicago.

Matthias Skillecorn is Area Managing Director for Janssen Southeast Asia. He leads a cross-functional team in SEA to drive the commercial strategies for Janssen’s portfolio. Matthias is a member of the Janssen Asia Pacific leadership team.

Matthias is no stranger to the region having served as Managing Director for J&J Vietnam since the beginning of 2021 where he led the completion of a business model transformation to a locally recognized Foreign Invested Enterprise. This included restructuring of the pharmaceuticals business to focus on our innovative portfolio, whilst continuing to drive growth of established brands through strategic partnerships with local distributors. These efforts have delivered strong double-digit growth in Vietnam.

Since May 2020, Matthias has also served as Portfolio Leader, Pharmaceuticals, Southeast Asia, where he led improved governance and portfolio discipline alongside the SEA Leadership Team, SEA Cross Functional Team and SEA Hospital Council.

Before moving to his regional roles, Matthias was Immunology Business Unit Director at Janssen Australia, where he led a team of 40 and served on the leadership team of Janssen Australia & New Zealand.

Matthias has over 20 years of experience in the pharmaceutical industry and has held many senior sales and marketing roles at Janssen and, previously, Eli Lilly, working in diverse therapeutic areas including Neuroscience, HIV, Renal, Transplant, Gastroenterology, Dermatology and Rheumatology.

Matthias was born in Sydney, Australia and holds a Master’s in Business Administration from the University of Technology, Sydney, and a Bachelor of Leisure Studies from the University of New South Wales.

Neelesh Shanbhag is currently the CIO & VP of Business Technology for Janssen Asia Pacific, he is responsible for the technology direction of the Pharmaceuticals group within Asia Pacific, developing and implementing effective IT strategies to support the overall growth objectives of the Pharmaceutical business in the region. He works closely with the leadership team in translating business priorities and challenges into technology solutions to better serve our patients and customers.

Most recently, Neelesh was the Global IT Integration Leader managing the overall technology integration of Actelion into the Janssen and wider J&J organization. He was responsible for developing the overall IT integration strategy, technology roadmap and implementation of key business capabilities across all functions. Leading in a period of uncertainty and complexity through the integration, he demonstrated a strong focus on cultivating an inclusive Credo-based and customer-centric culture.

Neelesh brings a 24-year track record of successful leadership in Technology in various roles and diverse cultures in Asia Pacific and EMEA regions. He started his Johnson & Johnson career in the Consumer sector in 1999; he assumed roles of increasing responsibilities within the IT organization across multiple regions, delivering critical business capabilities for the Pharma & Consumer business. Neelesh has played critical roles in major business transformation programs to help standardize the business processes and implement technology platforms to enable business growth.

Neelesh holds a Degree in Mechanical Engineering from Bangalore University and an MBA from the Macquarie Graduate School of Management in Sydney. He is also a Certified Supply Chain Professional from APICS, USA.

Oak Yeon Kim is Vice President, Commercial Strategies & Market Access for Janssen Asia Pacific and is a member of the Asia Pacific Leadership Team.

OakYeon began her career at Janssen in 1992 after completing a year as a Research Associate with the Korean FDA. She went on to hold a variety of roles with increasing responsibility, spending three years in the global marketing group in Beerse, Belgium and subsequently leading the marketing department at Janssen Korea.

In 2004, Oak Yeon was appointed as Head of Asia Pacific Regional Marketing where she led regional growth strategies across various therapeutic areas and played a key role in developing regional capabilities. 

After three successful years in the region, she was promoted to General Manager of Janssen Malaysia, where she led the business portfolio transition to focus on innovative medicines.

She then moved to Xian Janssen in China in 2010 to lead the General Medicines Business Unit where she demonstrated outstanding team-building and development skills, which inspired her team’s performance and business growth.

Oak Yeon then returned to Korea in the summer of 2012 to serve as Area Managing Director, Korea, Taiwan and Hong Kong.  Under her leadership, Janssen Korea showed excellent business- and cultural turn-around and led industry-level policy activities that have enhanced the environment for patients to access innovative medicines in Korea. Also, Janssen Taiwan and Hong Kong established their leadership positions in several innovative medicines.

Oak Yeon is an alumnus of Seoul National University and is based in Seoul.

Frances is Vice President of Janssen Medical Affairs for the Asia Pacific region and a member of the Asia Pacific Leadership Team.  She joined Janssen Japan as Vice President, Head of Medical Affairs, in 2020 after a long career in the pharmaceutical industry, transforming the function into a trusted and valued strategic business partner. She has ensured Janssen’s position as a scientific leader by instilling a growth mindset in the team, building capabilities, and establishing the Evidence Generation team. Frances is a great advocate of growing talent and is also passionate about Diversity, Equity and Inclusion (DE&I) in the workplace. As DE&I Lead for Janssen Japan, Frances collaborated with Jansen Japan MC to achieve significant improvement in female representation, particularly in management and leadership positions.

Prior to her career in the pharmaceutical industry, Frances worked at the Center for Drug Evaluation (CDE) in Taiwan as Medical Team Leader and Senior Medical Reviewer. Frances is a trained Medical Doctor in Internal Medicine, receiving her M.D. degree from the Beijing University of Chinese Medicine. She also holds a Ph.D. in Cardiovascular Disease from the China Academy of Chinese Medical Science.

Ricco Estanislao is responsible for the quality management and compliance of Janssen Pharmaceuticals in 21 countries across the Asia Pacific region. With 25 years’ experience in the combined FMCG and pharmaceutical industries, Ricco has extensive expertise in quality management, manufacturing, research and development, and clinical research.

A patent holder and author of several publications, Ricco’s work has been presented at several international meetings including to cosmetic scientists, dermatologists, other medical professionals, as well as manufacturing and quality experts.

Prior to his current role, Ricco held positions in the United States, Australia, China, Thailand and the Philippines.

Ricco holds a Bachelor’s Degree in Chemical Engineering from the University of the Philippines (Diliman), and a Master’s Degree in Business Administration from the University of Southern California Marshall School of Business. He is also a member of the International Honor Society Beta Gamma Sigma.

As Managing Director of Janssen India, Sarthak oversees the Company’s operations in India and the South Asian markets of Sri Lanka and Bangladesh. Sarthak is a member of the Johnson & Johnson (J&J) India President Council, as well as the Janssen Asia Pacific Leadership Team.

Sarthak joined Janssen as General Manager – Marketing in 2007. He went on to hold a variety of roles with increasing responsibility, including leadership roles at regional and country level.

From 2011-2014, he worked in the Janssen Asia Pacific Strategic Marketing team as Regional Commercial Director for Immunology, Metabolics and Established products and played a pivotal role in ensuring timely access to important medications for patients across the region.

He later relocated to Japan to take on the role of Senior Director of Marketing for Immunology, Pain & Infectious Diseases, again increasing access to our medicines and in turn delivering significant growth for the business. In 2016, he returned to his home country, India, as Vice President - Established Products, Metabolics, Immunology and Dermatology. In this role, he led multiple programs aimed at bringing our transformational medical innovations to the country.

With over 20 years’ pharmaceutical experience, Sarthak is a respected industry leader and currently chairs the Pharmaceutical Committee of the American Chambers of Commerce (AMCHAM) in India and is an Executive Council member of the Organisation of Pharmaceutical Producers of India (OPPI).

Sarthak holds a Master of Business Administration and a Bachelor of Pharmacy degree. A member of the 5am club, he also serves as a J&J India Health Champion and is committed to helping the company build the healthiest workforce in the country.

Shuhei is an experienced industry leader and advocate for the value of pharmaceutical innovation and importance of access to transformational medicines.

As President and Representative Director of Janssen Japan, Shuhei is responsible for leading Janssen’s second largest market globally and is also a member of the Asia Pacific Leadership Team.

Originally from Japan, Shuhei led the Janssen business in Taiwan from 2019 - 2021, where his focus on talent development and an inclusive culture strengthened the organization and drove significant business growth. During his time in Taiwan, Shuhei was President of the International Research-Based Pharmaceutical Manufacturers Association (IRPMA) and Co-chair of the American Chamber of Commerce in Taiwan’s Pharmaceutical Committee. In these roles, he advocated for innovation in the pharmaceutical industry and the importance of access to innovative healthcare in Taiwan.

Shuhei began his career with Johnson & Johnson in 2004 and has held various roles of increasing responsibility in Asia Pacific and at a global level, including leadership of the Janssen Japan Immunology and Infectious Diseases business from 2016-2019.

Shuhei holds an undergraduate degree from Dartmouth College and a Master of Business Administration from Duke University.

Young Sang “YS” Kwon is the Health Care Compliance (HCC) Regional Sector Lead (RSL) for Johnson & Johnson’s Pharmaceutical Group, Asia Pacific. In that capacity, he also oversees the compliance program for One J&J Southeast Asia. He assumed this role in February 2014.

In 2013, YS was appointed to the role of the HCC RSL for Johnson & Johnson’s Medical Device & Diagnostics Group, Asia Pacific, and before that he was the cross-sector HCC Cluster Lead for North Asia in 2012.

Prior to joining J&J in March 2012, YS was the Head of Legal and Compliance at LINA Korea, the Korean subsidiary of a US healthcare services company Cigna, from 2006 to 2011, where he oversaw the legal and compliance functions of Cigna’s Korea operation.

Before Cigna, YS was a lawyer with Kim & Chang, one of the largest law firms in Korea, where he advised clients in the areas of intellectual property law, corporate law and dispute resolution for more than seven years.

YS received a Bachelor of Arts degree from the Hankuk University of Foreign Studies in his native Korea, majoring in English Education with a minor in Economics in 1993. He obtained a Juris Doctor and a Master of Business Administration from Syracuse University in the USA.

Yuri is a highly experienced leader recognised for her strong financial acumen, ability to nurture growth and passion for inclusive workplaces.

As Vice President of Finance for Janssen Asia Pacific, Yuri Kato is responsible for providing financial stewardship for our business across Asia Pacific, leading teams in China, India, Japan, North Asia, Australia and New Zealand. She is also a member of the Global Pharmaceuticals Finance Leadership Team and the Asia Pacific Pharmaceuticals Leadership Team.

Previously, Yuri was Vice President for Finance & Business Development for Janssen Japan where she was instrumental in leading this key market towards accelerated growth.

Under her leadership, Janssen Japan created a solid financial foundation through proactive and agile resource allocation, strategic local partner alliance deals, and data-driven performance management which maximized current portfolio value and managed risk.  

Having worked in different parts of the world, Yuri truly appreciates workplaces that value cultural differences and has been instrumental in fostering a culture of diversity, equity and inclusion across the organization.

Yuri holds a bachelor's degree in sociology from Keio University.

As Head of Asia Pacific R&D, Zili oversees all R&D activities within Asia Pacific, leading over 1,400 science professionals dedicated to delivering transformational healthcare innovation across the region.

Zili joined Janssen in June 2019 from the U.S. Food and Drug Administration (FDA) where he served as Associate Director for Global Affairs at the Office of Generic Drugs. There he contributed significantly to the expansion of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) to the field of generic drugs, playing a critical role in China’s National Medical Products Administration’s membership in ICH in 2017.

Before rejoining the FDA in 2015, Zili had over 10 years of leadership and program management experience in pharmaceutical R&D at both Merck and the Bill and Melinda Gates Foundations, where he built high-performance and science-driven organizations and drove substantial increases in R&D productivity. At Merck, he served in positions of increasing responsibility in clinical development and regulatory affairs at global, regional and local levels. His roles included Medical Director of MSD China, Head of China and Asia Pacific Regulatory Policy, and Executive Director and Head of Emerging Markets Regulatory Strategy. At the Bill & Melinda Gates Foundation, Zili served as Deputy Director and Head of China R&D.

Zili first joined the FDA in 2000 as a medical reviewer for drug safety. Later he was promoted to medical team leader for overseeing IND and NDA reviews in defined therapeutic areas. In addition, Zili participated in FDA guidance development for the industry and presented at the FDA’s advisory committee meeting on behalf of the agency. Zili was a recipient of numerous FDA awards, including 2003 FDA Scientific Achievement Award and 2014 FDA Distinguished Alumni Award.

Zili is a graduate of Peking Union Medical College and completed his residency training at Johns Hopkins in 2000. In addition to his medical degree, Zili also holds two master’s degrees in public health.

As VP of Market Access, Steven leads the Janssen Asia Pacific Market Access team across strategy, pricing, real world evidence, health economics and policy.  Through stakeholder relationships, he works to develop optimal pricing and market access strategies, and shape the integrated evidence generation plans and pricing policies, to meet the needs of the region.  Steven is also responsible for developing the platforms and specific programs to advance the market access capabilities across the region, creating an environment where market access is prioritized as a critical capability. 

Steven joined Janssen Asia Pacific in 2020 as Senior Director, Therapeutic Area Market Access Lead for Oncology, Hematology and Ophthalmology, where he integrated and led the market access and pricing teams.  During this time, Steven leveraged effective collaboration with global stakeholders to shape the global pricing and market access strategies across wide-ranging pipeline assets, while playing a central role in many successful access initiatives.

Prior to joining Janssen, Steven built a long career in the pharmaceutical industry, serving in global pricing and market access leadership roles in oncology and hematology, as well as various roles across medical affairs and commercial.

Matt Sheroff and his team lead the evaluation process for regional business cases for mid- and late-stage assets for both regional and global business development (BD) opportunities, as well as supporting the ongoing life cycle management activities for Janssen’s established products portfolio.

Prior to joining Janssen Asia Pacific, Matt was Director of Oncology Transactions as part of the Janssen Business Team, with responsibility for leading the execution of clinical trial agreements, supply agreements and collaborations with industry partners, supporting external transactions, driving the development of BD strategies and tactics, and performing ad-hoc strategic analysis in support of the Oncology portfolio. 

Prior to joining the Janssen Business Development team, Matt was a member of the BD Finance team supporting several key transactions for the Oncology and ID&V therapeutic areas; and also spent several years supporting the Johnson & Johnson Vision Care Business in the US with roles in Finance, Supply Chain and Sales Reporting.

Matt is a graduate of Penn State University with a Bachelor’s degree in Finance.  He began his career at Johnson & Johnson in 2010 as part of the Financial Leadership Development Program.